Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Mustang Bio ( (MBIO) ).
At its 2025 Annual Meeting of stockholders held virtually on December 22, 2025, Mustang Bio shareholders approved all four proposals on the agenda, including the election of seven directors to serve until the 2026 annual meeting and the ratification of KPMG LLP as the company’s independent auditor for the year ending December 31, 2025. Investors also backed amendments to Mustang’s 2019 Employee Stock Purchase Plan, adding 250,000 issuable shares and increasing the shares subject to a Purchase Right to 10,000, and to its 2016 Incentive Plan, expanding the pool of issuable shares by 2,500,000, moves that enhance the company’s ability to use equity compensation in attracting and retaining talent. Separately, on December 17, 2025, Mustang and Fred Hutchinson Cancer Center agreed to terminate their CD20 License Agreement covering Mustang’s CD20 CAR-T program, with Mustang paying $730,000 to settle about $1.4 million in outstanding payables, and securing the right to receive at least 10% of any future consideration Fred Hutch obtains from third-party licenses of the former CD20 assets over the next three years, preserving some upside despite exiting the program.
Spark’s Take on MBIO Stock
According to Spark, TipRanks’ AI Analyst, MBIO is a Underperform.
Mustang Bio’s overall stock performance is hindered by significant financial instability, including zero revenues and continuous losses. While technical indicators suggest bearish momentum, the recent asset sale to AbbVie provides a glimmer of hope for cost reduction. However, the lack of earnings call data limits insights into future guidance, further emphasizing the need for caution.
To see Spark’s full report on MBIO stock, click here.
More about Mustang Bio
Mustang Bio, Inc. is a biotechnology company focused on developing cell- and gene-based therapies, including CAR-T programs, for cancer and other serious diseases. The company operates in the biopharmaceutical sector, leveraging licensed academic research and proprietary platforms to advance its pipeline of innovative treatments.
Average Trading Volume: 101,205
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.96M
For detailed information about MBIO stock, go to TipRanks’ Stock Analysis page.